BUDA ALESSANDRO ANTONIO

ESGO Member 2010-2011-2012-2013-2015-2016-2017-2018-2019-2020-2021-2022-
2023-2024; ESGE member 2010-2011; SIGO member 2012-2013-2014-2015-2016-
2017-2018-2019-2020; IGCS member 2015-17-18-19-20-21-22-23-24; SEGI e AOGOI
member from 2020 to date

SOFTWARE ABILITY WELL KNOWN PROGRAMS OF WINDOWS OFFICE E MAC;
Internet Explorer, WORD, P.POINT,ACCESS, EXCEL,SAS system version 6.12

International major publications
Principali pubblicazioni scientifiche
1) E Mari, I Floriani, A Tinazzi, A Buda, et al.
Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomise trials.
Ann Oncol 11: 837-843, 2000
2) The ICON Collaborators (A Buda, name listed in ICON group)
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin,
and cisplatin in women with ovarian cancer: the ICON3 randomised trial
The Lancet, 360: 505-515, 2002
3) MG Cantù, A Buda, G Parma, et al.
Randomised controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent
ovarian cancer who responded to first-line platinum-based regimens.
J Clin Oncol, 20 (5): 1232-1237, 2002
4) G Zanetta, S Rota, A Lissoni, A Meni, G Brancatelli and A Buda
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early
borderline ovarian tumors
Gynecol Oncol, 81: 63-66-2001
5) ICON1 and EORTC-ACTION collaborators (Alessandro Buda, name listed in ICON office Mario Negri Institute, Italy).
International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized
phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma
J Natl Cancer Inst 2003; 95: 105-112
6) ICON1 collaborators (A Buda, name listed in ICON office Mario Negri Institute, Italy)
International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian
cancer
J Natl Cancer Inst 2003; 95: 125-132
7) Buda A, Dell’Anna T, Signorelli M and Mangioni C
Role of ifosfamide in cervical cancer. an overview
Oncol, 65 (suppl. 2): 63-66, 2003
8) Manenti L, Paganoni P, Floriani I, Torri V, Buda A, Landoni F, Taraboletti G, Belotti D, Giavazzi R.
Expression level of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1
and 2 in plasma of patients with ovarian carcinoma.
Eur J Cancer , 39: 1948-1956, 2003
9) Torri V, Floriani I, Poli D, Santillo M, Buda A
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian
cancer: the ICON4/AGO-OVAR-2.2 trial.
Lancet , 361: 2099-2106 (362: 1504, 2003)
10) Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C.
Randomised controlled trial comparing single agent paclitaxel versus epidoxorubicin plus paclitaxel in patients with advanced
ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the “Mario Negri”
Institute, Milan, GONO (Gruppo Onclogico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group.
Br J Cancer, 90: 2112-2117, 2004
11) G Apolone, A Buda.
Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality of life evaluation?
Ann Oncol, 15(9):1443-4, 2004
12) G Cavaletti, G Bogliun, L Marzorati, A Zincone, M Piatti, N Colombo, D Franchi, MT La Presa, A Lissoni, A Buda,
F Fei, S Cundari, C Zanna.
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.
Ann Oncol. 15(9):1439-42, 2004.
13) Bonazzi C, Urso M, Dell’Anna T, Sacco S, Buda A, Cantu MG.
Placental site trophoblastic tumor: an overview.
J Reprod Med, 49(8):585-588, 2004
14) A Buda, R Fossati, N Colombo et al.
Randomized Trial of Neoadjuvant Chemotherapy Comparing a Three-Drug Combination of Paclitaxel, Ifosfamide, and
Cisplatin Versus Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous
Cell Cervical Carcinoma: The SNAP01 Italian Collaborative Study
J Clin Oncol, 23: 4137-4145 , 2005
15) S Sironi , A Buda, M Picchio, et al.
Lymph node metastasis in patients with clinical early stage cervical cancer: detection with integrated FDG PET/CT
Radiology 238 (1): 272-279, 2006
16) A Buda, L Ferrari, C Marra et al.
Vulvar endometriosis in surgical scar after excision of the Bartholin gland: report of a case.
Arch Gynecol Obstet 277 (3): 255-6, 2007
17) A Buda, G Pizzocaro, P Ceruti et al.
Case report: renal cell carcinoma presentino as hypertension in pregnancy.
Arch Gynecol Obstet 277 (3): 263-5, 2007
18) Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, Dell’anna T,
Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E.
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin
(TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma:
the Snap-02 Italian Collaborative Study.
Ann Oncol. 2009 Jan 30 ([Epub ahead of print]
19) Pellegrino A, Signorelli M, Fruscio R, Villa A, Buda A, Beretta P, Garbi A, Vitobello D.
Feasibility and morbidity of total laparoscopic radical hysterectomy with or without pelvic limphadenectomy in
obese women with stage I endometrial cancer.
Arch Gynecol Obstet. 2008 Sep 16. [Epub ahead of print]
20) A. A. Lissoni, N. Colombo, A. Pellegrino, G. Parma, P. Zola, D. Katsaros, S. Chiari, A. Buda et al.
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel,
ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally
advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study
Ann Oncol. 2009 Apr;20(4):660-5. Epub 2009 Jan 30.
21) Buda A, Pellegrino A, Vitobello D, Meroni MG, Recalcati D, Perego P.
Total laparoscopic radical parametrectomy, partial colpectomy, and pelvic lymphadenectomy in patients with
occult cervical cancer.
Int J Gynaecol Obstet. 2009 Oct;107(1):73-6. Epub 2009 Jun 24.
22) Signorelli M, Guerra L, Buda A, Picchio M, Mangili G, Dell’Anna T, Sironi S, Messa C.
Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage
endometrial cancer: detection of pelvic nodal metastases.
Gynecol Oncol. 2009 Nov;115(2):231-5. Epub 2009 Aug 19.
23) Signorelli M, Fruscio R, Dell’Anna T, Buda A, Giuliani D, Ceppi L, Milani R.
Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature
review.
Int J Gynecol Cancer. 2010 Nov;20(8):1363-6.22)
24) Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame
L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D’Incalci M.
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective
study of two independent tumour tissue collections.
Lancet Oncol. 2011 Mar;12(3):273-85. Epub 2011 Feb 21
25) Signorelli M, Guerra L, Montanelli L, Crivellaro C, Buda A, Dell’Anna T, Picchio M, Milani R, Fruscio R, Messa C
Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease?
Gynecol Oncol. 2011 Nov;123(2):236-40. Epub 2011 Aug 19

26) Misani M, Rovati LC, Confalonieri P, Buda A, Giuliani D, Del Bene M.
Modified lotus petal flap for vulvo-vaginal reconstruction after resection for vulvar cancer: a single institution
experience.
Handchir Mikrochir Plast Chir. 2011 Aug;43(4):250-4.
27) Buda A, Giuliani D, Montano N, Perego P, Milani R.
Primary insular carcinoid of the ovary with carcinoid heart disease: unfavorable outcome of a case.
International Journal of Surgery Case Reports 2012; 3(2): 59-61.
28) Alessandro Buda, Pier Luigi Confalonieri, Luca Carlo Vittorio Rovati, Robert Fruscio, Daniela Giuliani, Mauro
Signorelli,Tiziana Dell’Anna, Cecilia Pirovano, Rodolfo Milani
Better anatomical and cosmetic results using tunnelled lotus petal flap for plastic reconstruction after demolitive
surgery for vulvar malignancy.
Int J Gynecol Cancer 2012; 22 (5): 860-4
29) A Buda, R Fruscio, C Pirovano, M Signorelli, M Betti, R Milani.
TachoSil patch for the prevention of postoperative complications after groin dissection in gynecological
malignancy.
Int J Obstet Gynecol 2012; 117 (3): 217-9
30) Alessandro Buda, Federica Elisei, Maurizio Arosio, Carlotta Dolci, Mauro Signorelli, Patrizia Perego, Daniela
Giuliani, Dario Recalcati, Giorgio Cattoretti, Rodolfo Milani, Cristina Messa
Integration of hybrid SPECT/CT in the preoperative assessment of sentinel node in patients with uterine cancer:
our experience and literature review.
Int J Gynecol Cancer 2012; 22 (5): 830-5
31) Buda A, Confalonieri PL, Rovati LC, Signorelli M, Del Bene M.
Tunneled modified lotus petal flap for surgical reconstruction of severe introital stenosis after radical vulvectomy.
Int J Surg Case Rep. 2012;3(7):299-301.
32) Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M.
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
Am J Cancer Res. 2012;2(3):298-308.
33) Crivellaro C, Signorelli M, Guerra L, De Ponti E, Buda A, Dolci C, Pirovano C, Todde S, Fruscio R, Messa C.
18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer.
Gynecol Oncol. 2012; 127 (1): 131-5.
34) Dell’ Anna T, Signorelli M, Benedetti-Panici P, Maggioni A, Fossati R, Fruscio R, Milani R, Bocciolone L, Buda
A, Mangioni C, Scambia G, Angioli R,Campagnutta E, Grassi R, Landoni F.
Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.
Br J Cancer. 2012 Aug 21;107(5):785-92.
35) Crivellaro C, Signorelli M, Guerra L, De Ponti E, Pirovano C, Fruscio R, Elisei F, Montanelli L, Buda A, Messa C.
Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG
PET/CT.
Gynecol Oncol. 2013 Aug;130(2): 306-11.
36) Buda A, Elisei F, Dolci C, Cuzzocrea M, Milani R.
Uterine lymphatic drainage is unaffected from injection technique and operators: Identical sentinel node detection
in two cases of endometrial cancer.
Int J Surg Case Rep. 2013;4(8):697-9.
37) Fagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato VD, Petruzzelli F, Ghezzi F, Garzarelli S, Mereu L,
Viganò R, Tateo S, Fanfani F, Scambia G.
A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian
cancer.
Am J Obstet Gynecol. 2013 Nov;209(5):462.e1-462.e11.
38) Buda A, Cuzzocrea M, Dolci C, Elisei F, Baldo R, Locatelli L, Milani R, Messa C.
Sentinel node mapping in high risk endometrial cancer after laparoscopic supracervical hysterectomy with
morcellation.
Int J Surg Case Rep. 2013;4(10):809-12.
39) Signorelli M, Guerra L, Pirovano C, Crivellaro C, Fruscio R, Buda A, Cuzzucrea M, Elisei F, Ceppi L, Messa C.
Detection of nodal metastases by 18F-FDG PET/CT in apparent early-stage ovarian cancer: a prospective study.
Gynecol Oncol. 2013 Nov;131(2):395-9.
40) Buda A, Cuzzocrea M, Montanelli L, Passoni P, Bargossi L, Baldo R, Locatelli L, Milani R.
Evaluation of Patient Satisfaction Using the EORTC IN-PATSAT32 Questionnaire and Surgical Outcome in Single-
Port Surgery for Benign Adnexal Disease: Observational Comparison with Traditional Laparoscopy.
Diagn Ther Endosc. 2013;2013:578392.
41) Somaini M, Brambillasca P, Ingelmo PM, Lovisari F, Catenacci SS, Rossini V, Bucciero M, Sahillioglu E, Buda A,
Signorelli M, Gili M, Joshi GP, Fumagalli R, Ferland CE, Diemunsch P.
Effects of Peritoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Gynecologic Surgery.
J Minim Invasive Gynecol. 2014 Apr 8. pii: S1553-4650(14)00239-8.
42) Buda A, Guerra L, Signorelli M.
Regarding: “pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during
endometrial cancer staging”.
Int J Gynecol Cancer. 2014 Jul;24(6):964-5. doi: 10.1097/IGC.0000000000000159.
43) Buda A, Guerra L, Crivellaro C. Comment on ‘Pre-operative nomogram for the identification of lymph node
metastasis in early cervical cancer”.
Br J Cancer. 2014 Aug 14. doi: 10.1038/bjc.2014.284.
44) Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R,
Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R.
Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.
Cancer Res. 2014 Oct 10. pii: canres.0274.2014.
45) Scalia Catenacci S, Lovisari F, Peng S, Allegri M, Somaini M, Ghislanzoni L, Greco M, Rossini V, D’Andrea L, Buda
A, Signorelli M, Pellegrino A, Sportiello D, Bugada D, Ingelmo PM.
Postoperative Analgesia after Laparoscopic Ovarian Cyst Resection: Double-blind Multicenter Randomized Control
Trial Comparing Intraperitoneal Nebulization and Peritoneal Instillation of Ropivacaine.
J Minim Invasive Gynecol. 2015 Jul-Aug;22(5):759-66.
46) Signorelli M, Crivellaro C, Buda A, et al.
Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping.
Clin Nucl Med. 2015 Oct;40(10):780-5.
47) Buda A, Lissoni AA, Floriani I, et al
Long-Term Clinical Benefits of Neoadjuvant Chemotherapy in Women With Locally Advanced Cervical Cancer:
Validity of Pathological Response as Surrogate Endpoint of Survival.
Int J Gynecol Cancer. 2015 Oct;25(8):1468-75.
48) Buda A, Di Martino G, Vecchione F, et al.
Optimizing Strategies for Sentinel Lymph Node Mapping in Early-Stage Cervical and Endometrial Cancer:
Comparison of Real-Time Fluorescence With Indocyanine Green and Methylene Blue.
Int J Gynecol Cancer. 2015 Oct;25(8):1513-8.
49) Buda A, Bussi B, Di Martino G, et al.
Sentinel Lymph Node Mapping With Near-Infrared Fluorescent Imaging Using Indocyanine Green: A New Tool for
Laparoscopic Platform in Patients With Endometrial and Cervical Cancer.
J Minim Invasive Gynecol 2016; 23 (2): 265-9.
50) Buda A, Lissoni A, Milani R
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral vs cervical injection.
J Gynecol Oncol. 2016 Jan; 27(1):e11.
51) A Buda, C Crivellaro, F Elisei et al. Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early
Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer 99mTc and/or Blue Dye
Ann Surg Oncol, 2016; 23 (7): 2183-91.
52) A Buda, A Ghelardi, R Fruscio et al.
The contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after
groin lymphadenectomy: a double institution observational study.
Eur J Obstet Gynecol & Repr Biol 2016; 197: 156-8.
53) A Buda, Pierluigi Confalonieri, LC Rovati
Regarding: “Vulvar Reconstruction by Perforator Flaps. Algorithm for Flap Choice Based on the Topography of the
Defect”. Int J Gynecol Cancer 2016, 26 (2): 224-225.
54) Buda A, Dell’Anna T, Vecchione F, Verri D, Di Martino G, Milani R.
Near-Infrared Sentinel Lymph Node Mapping With Indocyanine Green Using the VITOM II ICG Exoscope for Open
Surgery for Gynecologic Malignancies.
J Minim Invasive Gynecol. 2016; 23 (4): 628-32.
55) Buda A, Elisei F, Palazzi S, et al.
Quality of Care for Cervical and Endometrial Cancer Patients: The Impact of Different Techniques of Sentinel
Lymph Node Mapping on Patient Satisfaction.
Ann Surg Oncol. 2016; 23 (9): 2975-81.
56) Buda A, Papadia A, Zapardiel I, et al.
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of
Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic
Approach.
Ann Surg Oncol. 2016; 23(9): 2959-65.
57) Buda A, Passoni P, Corrado G, et al.
Near-infrared Fluorescence-guided Sentinel Node Mapping of the Ovary With Indocyanine Green in a Minimally
Invasive Setting: A Feasible Study.
J Minim Invasive Gynecol. 2016; 24 (1): 165-70.
58) Papadia A, Zapardiel I, Bussi B, Ghezzi F, Ceccaroni M, De Ponti E, Elisei F, Imboden S, de la Noval BD, Gasparri
ML, Di Martino G, De Santiago J, Mueller M, Vecchione F, Dell’Orto F, Buda A.
Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping
identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye.
J Cancer Res Clin Oncol. 2016; 143 (3): 475-480.
59) Elisei F, Crivellaro C, Giuliani D, Dolci C, De Ponti E, Montanelli L, La Manna M, Guerra L, Arosio M, Landoni C,
Buda A.
Sentinel-node mapping in endometrial cancer patients: comparing SPECT/CT, gamma-probe and dye.
Ann Nucl Med 2017; 31 (1): 93-99.
60) Confalonieri P, Gilardi R, Rovati LC, Ceccherelli A, Lee JH, Magni S, Del Bene M, Buda A.
Comparison of V-Y advancement flap versus Lotus Petal Flap for plastic reconstruction after surgery in case of
vulvar malignancies: a retrospective single center experience.
Ann Plast Surg 2017: 79 (2): 186-191.
61) Di Martino G, Crivellaro C, De Ponti E, Bussi B, Papadia A, Zapardiel I, Vizza E, Elisei F, Diestro MD, Locatelli L,
Gasparri ML, Di Lorenzo P, Mueller M, Buda A.
Indocyanine Green versus Radiotracer with or without Blue Dye for Sentinel Lymph Node Mapping in Stage >IB1
Cervical Cancer (>2 cm).
J Minim Invasive Gynecol. 2017 May 29. pii: S1553-4650(17)30305-9.
62) Buda A, Passoni P, Reato C, Di Martino G.
Laparoscopic minimally invasive approach to sentinel lymph node mapping of the ovary using the near-infrared
fluorescent S1 HD Pinpoint system with indocyanine green dye.
J Minim Invasive Gynecol. 2017 Jul 29. doi: 10.1016/j.jmig.2017.07.018.
63) Buda A, Di Martino G, De Ponti E, Passoni P, Sina F, Reato C, Vecchione F, Giuliani D.
Laparoscopic Sentinel Node Mapping in Cervical and Endometrial Malignancies: a Case Control Study Comparing
Two Near-Infrared Fluorescence Systems.
J Minim Invasive Gynecol. 2017 Aug 11. doi: 10.1016/j.jmig.2017.08.011.
64) Papadia A, Gasparri ML, Buda A, Mueller MD.
Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid
and blue.
J Cancer Res Clin Oncol. 2017 Aug 21. doi: 10.1007/s00432-017-2501-8.
65) Alessandro Buda, Giampaolo Di Martino, Stefano Restaino, Elena De Ponti, Giorgia Monterossi, Daniela
Giuliani, Alfredo Ercoli, Federica Dell’Orto, Giorgia Dinoi, Tommaso Grassi, Giovanni Scambia, MD, Francesco
Fanfani.
The impact on survival of two different staging strategies in apparent early stage endometrial cancer comparing
sentinel lymph nodes mapping algorithm and selective lymphadenectomy: An Italian retrospective analysis of two
reference centers.
Gynecol Oncol 2017. Gynecol Oncol. 2017 Oct 9. doi: 10.1016/j.ygyno.2017.09.033.
66) Di Martino G, Reato C, Verri D, Dell’Orto F, Buda A
Laparoscopic typical and atypical locations of sentinel node mapping with indocyanine green: comparison of two
near-infrared flourescence systems.
J Minim Invasive Gynecol. 2017 Sep 19. doi: 10.1016/j.jmig.2017.09.011.
67) Uccella S, Buda A, Morosi C, et al.
Minilaparoscopy vs. standard laparoscopy for sentinel node dissection: a pilot study.
J Min Invasive Gynecol 2017. Oct 13. DOI: 10.1016/j.jmig.2017.10.003
68) Montanelli L, Reato C, Mauro S, Meregalli S, Spallino M, Buda A.
A Rare Case Report: Isolated Mediastinal Lymph Node Recurrence in High-Risk Endometrial Cancer at 5 Years after
Primary Laparoscopic Surgery.
J Minim Invasive Gynecol. 2018; 25 (3): 537-540.
69) Crivellaro C, Guglielmo P, De Ponti E, Elisei F, Guerra L, Magni S, La Manna M, Di Martino G, Landoni C, Buda A.
18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective?
Medicine (Baltimore). 2017; 96 (38): e7943.
70) Alessandro Buda, Maria Luisa Gasparri, Andrea Puppo, et al.
Lymph node evaluation in high-risk early-stage endometrial cancer: a multi-institutional retrospective analysis
comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy.
Gynecol Oncol 2018, 150 (2): 261-266
71) De Bernardi E, Buda A, Guerra L, Vicini D, Elisei F, Landoni C, Fruscio R, Messa C, Crivellaro C.
Radiomics of the tumor as a tool to improve 18F-FDG-PET sensitivity in detecting nodal metastases in endometrial
cancer.
EJNMMI Res. 2018 Aug 22;8 (1):86. doi: 10.1186/s13550-018-0441-1.
72) Buda A, Restaino S, Di Martino G, et al.
The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk
ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study.
Eur J Surg Oncol. 2018 Jul 24. pii: S0748-7983(18)31187-9. doi: 10.1016/j.ejso.2018.06.034.
73) Papadia A, Buda A, Gasparri ML, Di Martino G, Bussi B, Verri D, Mueller MD.
The impact of different doses of indocyanine green on the sentinel lymph-node mapping in early stage
endometrial cancer.
J Cancer Res Clin Oncol. 2018 Jul 24. doi: 10.1007/s00432-018-2716-3.
74) De Bernardi E, Buda A, Guerra L, et al.
Radiomics of the primary tumour as a tool to improve 18-FDG-PET sentitivity in detecting nodal metastases in
endometrial cancer
EJNMMI Res. 2018 22; 8 (1): 86. doi: 10.1186/s13550-018-0441-1.
75) Buda A, Restaino S, Di Martino G, et al.
The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk
ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study.
Eur J Surg Oncol. 2018; 44 (10): 1562-1567.
76) Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D,
Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A.
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.
N Engl J Med. 2018 5;379 (20): 1895-1904.
77) Delle Marchette M, Ceppi L, Andreano A, Bonazzi CM, Buda A, Grassi T, Giuliani D, Sina F, Lamanna M, Bianchi
T, Lissoni AA, Landoni F, Valsecchi MG, Fruscio R.
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing
surgery.
Eur J Cancer. 2019; 111:61-68.
78) Peiretti M, Candotti G, Buda A, Zapardiel I, Fanni D, Proto A, Fais ML, Mais V.
Feasibility of hand-assisted laparoscopic sentinel node biopsy in open endometrial cancer surgery.
Minim Invasive Ther Allied Technol. 2020; 29(5):299-303.
79) Guglielmo P, Paderno M, Elisei F, Guerra L, Landoni C, Buda A, Crivellaro C.
18F-FDG PET/CT in a Case of Metastatic Breast Cancer to the Vulva.
Clin Nucl Med. 2019; 44(7):572-573.
80) Dell’Orto F, Laven P, Delle Marchette M, Lambrechts S, Kruitwagen R, Buda A.
Feasibility of sentinel lymph node mapping of the ovary: a systematic review.
Int J Gynecol Cancer. 2019; 29(7):1209-1215.
81) Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A,
Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M,
Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT.
Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a
randomized controlled trial.
Am J Obstet Gynecol. 2020; 222(3):249.e1-249.e10.
82) Fanfani F, Monterossi G, Di Meo ML, La Fera E, Dell’Orto F, Gioè A, Lamanna M, Ferrari D, De Ponti E, Perego P,
Restaino S, Carlo R, Zannoni GF, Landoni F, Scambia G, Buda A.
Standard ultra-staging compared to one-step nucleic acid amplification for the detection of sentinel lymph node
metastasis in endometrial cancer patients: a retrospective cohort comparison.
Int J Gynecol Cancer. 2020; 30(3):372-377.
83) Crivellaro C, Landoni C, Elisei F, Buda A, Bonacina M, Grassi T, Monaco L, Giuliani D, Gotuzzo I, Magni S, Di
Martino G, Delle Marchette M, Guerra L, Landoni F, Fruscio R, Messa C, De Bernardi E.
Combining positron emission tomography/computed tomography, radiomics, and sentinel lymph node mapping
for nodal staging of endometrial cancer patients.
Int J Gynecol Cancer. 2020; 30(3):378-382.
84) Frumovitz M, Buda A.
Encouraging worldwide adoption of sentinel lymph node biopsies for gynecologic malignancies.
Int J Gynecol Cancer. 2020;30(3):281-282.
85) Cola A, Milani R, Buda A, Manodoro S, Barba M, Frigerio M.
Surgical treatment of complete uterovaginal prolapse and concomitant vaginal cancer: a video case report.
Int Urogynecol J. 2020 Aug;31(8):1703-1705.
86) Buda A, Yaprak E, MIlani R, Frigerio M, Perego R, Jaconi M, Meregalli S.
Locally-advanced vaginal cancer with complete utero-vaginal prolapse.
Int J Gynecol Cancer. 2020 May;30(5):705-708.
87) Abu-Rustum NR, Angioli R, Bailey AE, Broach V, Buda A, Coriddi MR, Dayan JH, Frumovitz M, Kim YM, Kimmig
R, Leitao MM Jr, Muallem MZ, McKittrick M, Mehrara B, Montera R, Moukarzel LA, Naik R, Pedra Nobre S, Plante
M, Plotti F, Zivanovic O.
IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and
the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers.
Int J Gynecol Cancer. 2020; 30(5):670-683.
88) Nemejcova K, Kocian R, Kohler C, Jarkovsky J, Klat J, Berjon A, Pilka R, Sehnal B, Gil-Ibanez B, Lupo E, Petiz A,
Sanchez OA, Kascak P, Martinelli F, Buda A, et al.
Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node
Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2).
Cancers (Basel). 2020; 29: 12(5):1115.
89) Grassi T, Dell’Orto F, Jaconi M, Lamanna M, De Ponti E, Paderno M, Landoni F, Leone BE, Fruscio R, Buda A.
Two ultrastaging protocols for the detection of lymph node metastases in early-stage cervical and endometrial
cancers.
Int J Gynecol Cancer. 2020 Sep;30(9):1404-1410.
90) Frumovitz M, Obermair A, Coleman RL, Pareja R, Lopez A, Ribero R, Isla D, Rendon G, Bernardini MQ, Buda A,
Moretti-Marquez R, Zevallos A, Vieira MA, Zhu T, Land RP, Nicklin J, Asher R, Robledo KP, Gebski V, Ramirez PT.
Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a
secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.
Lancet Oncol. 2020; 21(6):851-860.
91) Zapardiel I, Iacoponi S, Coronado PJ, Zalewski K, Chen F, Fotopoulou C, Dursun P, Kotsopoulos IC, Jach R, Buda
A, et al.
Prognostic factors in patients with vulvar cancer: the VULCAN study.
Int J Gynecol Cancer. 2020; 30(9):1285-1291.
92) Casarin J, Buda A, Bogani G, Fanfani F, Papadia A, Ceccaroni M, Malzoni M, Pellegrino A, Ferrari F, Greggi S,
Uccella S, Pinelli C, Cromi A, Ditto A, Di Martino G, Anchora LP, Falcone F, Bonfiglio F, Odicino F, Mueller M,
Scambia G, Raspagliesi F, Landoni F, Ghezzi F.
Predictors of recurrence following laparoscopic radical hysterectomy for early-stage cervical cancer: A multi-
institutional study.
Gynecol Oncol. 2020; 159(1):164-170.
93) Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre,
observational trial of patients with cervical cancer: The SENTIX trial.
Cibula D, Kocian R, Plaikner A, Jarkovsky J, Klat J, Zapardiel I, Pilka R, Torne A, Sehnal B, Ostojich M, Petiz A,
Sanchez OA, Presl J, Buda A, Raspagliesi F, Kascak P, van Lonkhuijzen L, Barahona M, Minar L, Blecharz P, Pakiz M,
Wydra D, Snyman LC, Zalewski K, Zorrero C, Havelka P, Redecha M, Vinnytska A, Vergote I, Tingulstad S, Michal M,
Kipp B, Slama J, Marnitz S, Bajsova S, Hernandez A, Fischerova D, Nemejcova K, Kohler C.
Eur J Cancer. 2020 Sep;137:69-80.
94) Zapardiel I, Gracia M, Díez J, Buda A, Noya MC, Iaco P, Vieira-Baptista P, Iacoponi S; VULCAN Study
collaborative group.
Prognostic factors for recurrence and survival in uncommon variants of vulvar cancer.
Arch Gynecol Obstet. 2020 Oct 16. doi: 10.1007/s00404-020-05813-x.
95) Ceppi L, Grassi T, Galli F, Buda A, Aletti G, Lissoni AA, Adorni M, Garbi A, Colombo N, Bonazzi C, Landoni F,
Fruscio R.
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory
analysis in two oncology centers.
Gynecol Oncol. 2020; S0090-8258(20)34036-1.
96) Buda A, Cesarin J, Mueller M, Fanfani F, Zapardiel I, Mereu L, Puppo A, De Ponti E, Adorni M, Ferrari D,
Gasparri ML, Ghezzi F, Scambia G, Papadia A.
The impact of low-volume metastasis on disease-free survival of women with early-stage cervical cancer.
J Cancer Res Clin Oncol. 2020 Nov 1. doi: 10.1007/s00432-020-03435-z.
97) Moloney K, Janda M, Frumovitz M, Leitao M, Abu-Rustum NR, Rossi E, Nicklin JL, Plante M, Lecuru FR, Buda A,
et al.
Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive
surgery for endometrial cancer.
Int J Gynecol Cancer. 2021 Mar 4:ijgc-2020-002315. doi: 10.1136/ijgc-2020-002315.
98) Fanfani F, Pedone Anchora L, Di Martino G, Bizzarri N, Di Meo ML, Carbone V, Paderno M, Fedele C, Paniga C,
Fagotti A, Landoni F, Scambia G, Buda A.
Oncologic and obstetric outcomes after simple conization for fertility-sparing surgery in FIGO 2018 stage IB1
cervical cancer.
Int J Gynecol Cancer. 2021 Mar;31(3):452-456. doi: 10.1136/ijgc-2020-001750.
99) Ghoniem K, Larish AM, Dinoi G, Zhou XC, Alhilli M, Wallace S, Wohlmuth C, Baiocchi G, Tokgozoglu N,
Raspagliesi F, Buda A, et al.
Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An
international multi-institutional study.
Gynecol Oncol. 2021 Sep;162(3):590-598. doi: 10.1016/j.ygyno.2021.06.031. Epub 2021 Jul 15.
100) Bogani G, Papadia A, Buda A, et al.
Factor predicting morbidity in surgically staged high-risk endometrial cancer patients.
Eur J Obstet Reprod Biol 2021; 266: 169-174.
101) Guani B, Mahiou K, Crestani A, Cibula D, Buda A, et al.
Clinical impact of low-volume lymph node metastasis in early-stage cervical cancer: a comprehensive meta-
analysis.
Gynecol Oncol 2022, 164: 446-454.
102) Restaino S, Buda A, et al.
Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study.
Int J Gynecol Cancer. 2022; 32 (4): 517-24.
103) Buda A, Di Martino G, Borghese M, et al.
Low-Pressure Laparoscopy Using the AirSeal System versus Standard Insufflation in Early-Stage Endometrial
Cancer: A Multicenter, Retrospective Study (ARIEL Study).
Healthcare, 2022; 14;10(3):531. doi: 10.3390/healthcare10030531.
104) Buda A, Borghese M, Puppo A, et al.
Neoadjuvant Chemotherapy Prior Fertility-Sparing Surgery in Women with FIGO 2018 Stage IB2 Cervical Cancer: A
Systematic Review.
Cancers, 2022; 14(3):797. doi: 10.3390/cancers14030797.

105) Bogani G, Di Donato V, Papadia A, Buda A, et al.
Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer.
Gynecol Oncol. 2022 Jun 17:S0090-8258(22)00407-3. doi: 10.1016/j.ygyno.2022.06.007.
106) Zola P, Ciccone G, Piovano E, Fuso L, Di Cuonzo D, Castiglione A, Pagano E, Peirano E, Landoni F, Sartori E,
Narducci F, Bertetto O, Ferrero A, Angioli R, Berretta R, Borra G, Buda A, et al.
Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer
(TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial. J Clin Oncol. 2022 Nov 20;40(33):3817-
3827.
107) Burg LC, Verheijen S, Bekkers RLM, IntHout J, Holloway RW, Taskin S, Ferguson SE, Xue Y, Ditto A, Baiocchi G,
Papadia A, Bogani G, Buda A, Kruitwagen RFPM, Zusterzeel PLM.
The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer
management: a systematic review and meta-analysis.
J Gynecol Oncol. 2022 Sep;33(5):e66.
108) Restaino S, Mauro J, Zermano S, Pellecchia G, Mariuzzi L, Orsaria M, Titone F, Biasioli A, Della Martina M,
Andreetta C, Poletto E, Arcieri M, Buda A, Driul L, Vizzielli G
CUP-syndrome: Inguinal high grade serous ovarian carcinoma lymph node metastases with unknown primary
origin – a case report and literature review.
Front Oncol. 2022 Oct 10;12:987169.
109) Bazzurini L, Ornaghi S, Colciago E, Penati C, di Gennaro F, Passoni P, Buda A, Locatelli A, Landoni F, Vergani P.
Endometriosis-related spontaneous hemoperitoneum in pregnancy: A case series.
J Obstet Gynaecol Res. 2023 Feb;49(2):744-752. doi: 10.1111/jog.15498. Epub 2022 Nov 11.
110) Bogani G, Di Donato V, Papadia A, Buda A, et al.
Hysterectomy alone vs. hysterectomy plus sentinel node mapping in endometrial cancer: Perioperative and long-
term results from a propensity-score based study.
Eur J Surg Oncol. 2023 May;49(5):1037-1043.
111) Restaino S, Paglietti C, Arcieri M, Biasioli A, Della Martina M, Mariuzzi L, Andreetta C, Titone F, Bogani G,
Raimondo D, Perelli F, Buda A, Petrillo M, Greco P, Ercoli A, Fanfani F, Scambia G, Driul L, Vizzielli G.
Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines.
The Udine Hospital Gynecological-Oncological Tumor Board Group.
Cancers (Basel). 2023 Feb 8;15(4):1091.
112) Buda A, Paniga C, Taskin S, et al.
The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes:
A Retrospective Multi-Institutional Study.
Cancers (Basel). 2023 Mar 30;15(7):2052.
113) Buda A, Fanfani F
The patterns of growth of cervical cancer: a challenge to personalized radical surgery.
Int J Gynecol Cancer. 2023 Jul 3;33(7):1162-1163.
114) Mauro J, Viveros-Carreño D, Vizzielli G, De Ponti E, Fanfani F, Ramirez PT, Buda A.
Survival after sentinel node biopsy alone in early-stage cervical cancer: a systematic review.
Int J Gynecol Cancer. 2023 Sep 4;33(9):1370-1375.
115) Buda A, Signorelli M, Papadia A.
Correspondence on ‘Long-term survival outcomes in high-risk endometrial cancer patients undergoing sentinel
lymph node biopsy alone versus lymphadenectomy’ by Capozzi et al.
Int J Gynecol Cancer. 2023 Oct 2;33(10):1668-1669.
116) Bruno V, Betti M, D’Ambrosio L, Massacci A, Chiofalo B, Pietropolli A, Piaggio G, Ciliberto G, Nisticò P, Pallocca
M, Buda A, Vizza E.
Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical
Oncology with the tumor immune framework.
Int J Gynecol Cancer. 2023 Nov 6;33(11):1708-1714.
117) Mauro J, Filipello F, Tripodi E, Di Guardia G, Buda A.
Serous endometrial cancer confined to a polyp with malignant pleural effusion.
Int J Gynecol Cancer. 2023 Nov 6;33(11):1812-1818.
118) Borghi C, Biagioli E, Mauro J, Roberto A, Borghese M, Buda A.
Neoadjuvant chemotherapy prior to radical hysterectomy in locally advanced cervical cancer: a systematic review
and meta-analysis.
Int J Gynecol Cancer. 2023 Nov 27:ijgc-2023-004863.
119) Cucinella G, Schivardi G, Zhou XC, AlHilli M, Wallace S, Wohlmuth C, Baiocchi G, Tokgozoglu N, Raspagliesi F,
Buda A, et al.
Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an
international multi-institutional study.
Int J Gynecol Cancer. 2023 Dec 7:ijgc-2023-005032.
120) Mauro J, Borghi C, Surace A, Buda A.
Laparoscopic ovarian sentinel lymph node mapping using indocyanine green for ovarian restaging purpose.
Int J Gynecol Cancer. 2024 Jan 18:ijgc-2023-004908.
121) Mauro J, Raimondo D, Di Martino G, Gasparri ML, Restaino S, Neola D, Clivio L, Calidona C, Fruscio R, Vizzielli
G, Uccella S, Papadia A, Seracchioli R, Buda A.
Assessment of sentinel Lymph node mapping with different volumes of Indocyanine green in early-stage
ENdometrial cancer: the ALIEN study.
Int J Gynecol Cancer. 2024 Mar 25:ijgc-2023-005100.
122) Bizzarri N, Obermair A, Hsu HC, Chacon E, Collins A, Tsibulak I, Mutombo A, Abu-Rustum NR, Balaya V, Buda
A, et al.
Consensus on surgical technique for sentinel lymph node dissection in cervical cancer.
Int J Gynecol Cancer. 2024 Feb 20:ijgc-2023-005151.
123) Śniadecki M, Guani B, Jaworek P, Klasa-Mazurkiewicz D, Mahiou K, Mosakowska K, Buda A, et al.
Tertiary prevention strategies for micrometastatic lymph node cervical cancer: A systematic review and a
prototype of an adapted model of care.
Crit Rev Oncol Hematol. 2024 Mar 23:104329
124) Restaino S, Poli A, Arcieri M, Mariuzzi L, Orsaria M, Tulisso A, Pellecchia G, Paparcura F, Petrillo M, Bogani G,
Cianci S, Capozzi VA, Biasioli A, Buda A, Mauro J, Fanfani F, Fagotti A, Driul L, Scambia G, Vizzielli G.Molecular
classification of endometrial carcinoma on endometrial biopsy: an early prognostic value to guide personalized
treatment.
Int J Gynecol Cancer. 2024 Aug 5;34(8):1211-1216.
125) Restaino S, Pellecchia G, Arcieri M, Bogani G, Taliento C, Greco P, Driul L, Chiantera V, Ercoli A, Fanfani F,
Fagotti A, Ciavattini A, Scambia G, Vizzielli G; Gynecologic Oncology Group.
Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific
Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO).
Cancers (Basel). 2024 Jul 15;16(14):2541. doi: 10.3390/cancers16142541.
126) Bruno V, Betti M, Mauro J, Buda A, Vizza E.
Biomolecular Classification in Endometrial Cancer: Onset, Evolution, and Further Perspectives: A Critical Review.
Cancers (Basel). 2024 Aug 25;16(17):2959. doi: 10.3390/cancers16172959.
127) Buda A, Fruscio R, Mauro J, et al. The impact of Substantial LYMphovascular space invasion on sentinel lymph
nodes status and recurrence in Endometrial Cancer patients: SLYM-EC a multicenter retrospective study.
Eur J Surg Oncol. 2024 Dec;50(12):108731. doi: 10.1016/j.ejso.2024.108731.
128) Buda A, Mauro J, Varvello F, Antolini J, Di Guardia G, Bar E, Filipello F, Milani R.
Conservative Resolution of a Vesicovaginal Fistula Including Laser Therapy in a Patient Who Underwent Recurrent
Surgery After Prior Radiotherapy for Endometrial Cancer.
Cancer Rep (Hoboken). 2024 Nov;7(11):e70056. doi: 10.1002/cnr2.70056.
129) De Vitis LA, Bogani G, Raspagliesi F, Arencibia Sanchez O, Navarro B, Multinu F, Zanagnolo V, Baiocchi G, De
Brot L, Fanfani F, Capasso I, Piedimonte S, DeGuerke L, Buda A, et al.
Outcomes of low-risk endometrial cancer with isolated tumor cells in the sentinel lymph nodes: a prospective,
multi-center, single-arm, observational study (ENDO-ITC study).
Low Volume Metastasis in Endometrial Cancer Consortium.
Int J Gynecol Cancer. 2025 Aug;35(8):101764. doi: 10.1016/j.ijgc.2025.101764.
130) Mauro J, Mueller M, Perrone E, Bruno V, Restaino S, De Ponti E, Imboden S, Garcia-Pineda V, Taskin S, Grassi
T, Siegenthaler F, Casarin J, Raimondo D, Capozzi VA, Vatansever D, Capasso I, Vizza E, Gungor M, Zapardiel I,
Papadia A, Fruscio R, Taskiran C, Vizzielli G, Fanfani F, Scambia G, Buda A.
SLYMEC II study: Overall survival analysis of the impact of LVSI in apparent early stage endometrioid endometrial
cancer.
Eur J Surg Oncol. 2025 Jul;51(7):109750. doi: 10.1016/j.ejso.2025.109750.
131) Bizzarri N, Schivardi G, Di Martino G, Antonacci A, Querleu D, Pedone Anchora L, Ferrandina G, Fedele C,
Carbone V, Casarin J, Buda A, Zanagnolo V, Multinu F, Testa F, Landoni F, Scambia G, Fanfani F.
Factors associated with bilateral sentinel lymph node mapping failure using indocyanine green in patients with
apparent early-stage cervical cancer: An Italian retrospective multi-center study.
Eur J Surg Oncol. 2025 Jul;51(7):109981. doi: 10.1016/j.ejso.2025.109981.
132) Mauro J, Filipello F, Borghi C, Di Guardia G, Buda A.
Primary mixed carcinoid tumor arising in a mature ovarian teratoma.
Int J Gynecol Cancer. 2025 May;35(5):101806. doi: 10.1016/j.ijgc.2025.101806.
133) Cucinella G, Schivardi G, Zhou XC, AlHilli MM, Wallace S, Covens A, Wohlmuth C, Baiocchi G, Tokgozoglu N,
Raspagliesi F, Buda A, et al.
Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results
from an international, multi-institutional study.
Int J Gynecol Cancer. 2025 Jul;35(7):101906. doi: 10.1016/j.ijgc.2025.101906.
134) Restaino S, Poli A, Arcieri M, Mariuzzi L, Tulisso A, Paparcura F, Pellecchia G, Berretta R, Capozzi VA, Di Donato
V, Buda A, Bogani G, Fanfani F, Driul L, Orsaria M, Vizzielli G.
Exploring the cost-effectiveness of the OSNA method for patients facing endometrial cancer: Insights from a single-
institution experience.
Eur J Surg Oncol. 2025 Sep;51(9):110192. doi: 10.1016/j.ejso.2025.110192.
135) Paracchini S, Taliento C, Pellecchia G, Tius V, Tavares M, Borghi C, Buda AA, Bartoli A, Bourdel N, Vizzielli G.
Artificial intelligence in the operating room: A systematic review of AI models for surgical phase, instruments and
anatomical structure identification.
Acta Obstet Gynecol Scand. 2025 Aug 27. doi: 10.1111/aogs.70045. Online ahead of print.

Riconoscimenti, libri e collaborazioni scientifiche
1) F Landoni, F Vecchione, T Dell’Anna, C Mangioni, C Bonazzi, A Buda, M Zoccatelli.
I tumori dell’ovaio.
In Trattato di Chirurgia Oncologica, Capitolo 74; Vol III. Ed. Piccin 2002.
2) Clinical Evidence: Translation CE FULL TEXT chapters on women health
In Clinical Evidence, Italian Edition, 3, 2005 (edizione integrale online: http://aifa.clinev.it)
3) Clinical Evidence: Translation CE FULL TEXT chapters on women health
In Clinical Evidence, Italian Edition, 4, 2006 (edizione integrale online: http://aifa.clinev.it)
4) DVD entitled: totally laparoscopic radical hysterectomy with pelvic lymphadenectomy.
Pellegrino A, Vitobello D, Meroni M, N Iedà, A Buda. Istituto di scienze Biomediche,
Università degli Studi Milano-Bicocca, San Gerardo dei Tintori Monza,
Clinica di Ostetricia e Ginecologia
In collaborazione con AB Medica, Cooper Surgical, Gyrus Acmi, Taut, Vims, 2007
5) Dell’Anna TT, Buda A, Floriani I.
Adjuvant chemotherapy for endometrial cancer.
Cochrane Database of Systematic Reviews 2001, Issue 3. DOI: 10.1002/14651858.CD003175.
6) Trattato di chirurgia ostetrica e ginecologica. G Scambia, P Scollo, E Vizza.
Capitolo eviscerazione pelvica con Prof F Landoni. Ed Edra, 2019
7) ESGO Recognition Certificate in Gynecologic Oncology. ESGO Society 2023